The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.

• Status: Recruiting
• Trial end date: 2022-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of this study is to evaluate the efficacy of 25 mg of psilocybin under supportive conditions to adult participants with BP-II, current episode depressed, in improving depressive symptoms.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sheppard Pratt Health System
• Collaborator: COMPASS Pathways
• Treatments: Psilocybin

Criteria

Inclusion Criteria:

• Diagnosis of Type 2 Bipolar Disorder (BP-II) Depression

Exclusion Criteria:

• Comorbidities